Multiple biopsies increase infection risk for prostate cancer patients

This article originally appeared here.
Repeat Biopsies Up Infection Risk in Prostate Cancer Patients
Repeat Biopsies Up Infection Risk in Prostate Cancer Patients

MONDAY, Feb. 24, 2014 (HealthDay News) -- For men with prostate cancer who are under active surveillance, repeated biopsies are associated with increased risk of infectious complications, according to research published in the March issue of The Journal of Urology.

Behfar Ehdaie, M.D., of the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues prospectively analyzed data for 591 consecutive patients who underwent prostate biopsy. The authors sought to assess the risk of infectious complications associated with repeat biopsies in active surveillance for prostate cancer.

The researchers found that 14 patients (3.5 percent) had infectious complications (some resulting in hospitalization) from prostate biopsy. Urine cultures were positive in five patients; fluoroquinolone-resistant isolates were detected in four patients, including two patients with extended spectrum beta-lactamase producing isolates. The number of previous prostate biopsies was significantly associated with increased risk of infectious complications (odds ratio, 1.33; 95 percent confidence interval, 1.01 to 1.74).

"The management of men with low-risk prostate cancer on active surveillance requires serial repeat biopsies, which exposes these men to infectious complications with each biopsy," the authors write. "Men with prostate cancer on active surveillance should be informed of the risks associated with serial repeat prostate biopsies."

One author disclosed financial ties to Steba Biotech.

Full Text

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs